Literature DB >> 17904337

Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study.

Luis San1, Antonio Ciudad, Enrique Alvarez, Julio Bobes, Inmaculada Gilaberte.   

Abstract

PURPOSE: Progress in therapeutic options for schizophrenia has revived long-term expectations of researchers, practitioners and patients. At present, definitions of therapeutic outcome include both maintained symptomatic remission and appropriate functioning in a conceptual framework that targets patient's recovery as the ultimate goal. We aimed to know the prevalence and clinical features of patients with schizophrenia achieving these outcomes.
METHODS: A multi-centre, cross-sectional study was performed in more than 100 mental health facilities within Spain. Recently published consensus-based operational criteria for symptomatic remission and the Global Assessment of Functioning scale were used to evaluate outcomes. Other clinical aspects like depressive symptoms, social cognition, premorbid adjustment and patients' attitudes to medication were also evaluated.
RESULTS: Data from 1010 patients were analysed. Of these, 452 (44.8%) were at clinical remission, but only 103 (10.2%) showed an adequate social and/or vocational functioning. Factors predicting both outcomes were better pre-morbid adjustment (odds ratio, OR=1.56) and better social cognitive function (OR=1.14). Other factors, like treatment adherence, current or past psychotherapy and patient's age were not associated to functionality but only to clinical remission. Current substance use and previous rehabilitation were associated to a lower likelihood of symptomatic remission.
CONCLUSION: Although symptomatic remission in patients with schizophrenia is a realistic and reachable goal, future efforts should be directed to a sustained appropriate functioning in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904337     DOI: 10.1016/j.eurpsy.2007.06.005

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  29 in total

Review 1.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

2.  Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.

Authors:  Prakash S Masand; Miquel Roca; Martin S Turner; John M Kane
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

3.  Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methods.

Authors:  Rebecca Schennach; Hans-Jürgen Möller; Michael Obermeier; Florian Seemüller; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Richard Musil; Ilja Spellmann; Michael Riedel
Journal:  Int J Methods Psychiatr Res       Date:  2015-07-14       Impact factor: 4.035

4.  Predictors and Prevalence of Recovery and Remission for Consumers Discharged from Mental Hospitals in a Chinese Society.

Authors:  Daniel K W Young; Petrus Y N Ng; Jiayan Pan
Journal:  Psychiatr Q       Date:  2017-12

5.  The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients.

Authors:  Silvana Galderisi; Paola Rucci; Armida Mucci; Alessandro Rossi; Paola Rocca; Alessandro Bertolino; Eugenio Aguglia; Mario Amore; Antonello Bellomo; Paola Bozzatello; Paola Bucci; Bernardo Carpiniello; Enrico Collantoni; Alessandro Cuomo; Liliana Dell'Osso; Fabio Di Fabio; Massimo di Giannantonio; Dino Gibertoni; Giulia Maria Giordano; Carlo Marchesi; Palmiero Monteleone; Lucio Oldani; Maurizio Pompili; Rita Roncone; Rodolfo Rossi; Alberto Siracusano; Antonio Vita; Patrizia Zeppegno; Mario Maj
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

6.  Empowerment and its associations in schizophrenia: a cross-sectional study.

Authors:  Amlan Kusum Jana; Daya Ram; Samir Kumar Praharaj
Journal:  Community Ment Health J       Date:  2014-05-03

7.  Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial.

Authors:  Rebecca Schennach; Michael Riedel; Michael Obermeier; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Florian Seemüller; Hans-Jürgen Möller
Journal:  Psychiatr Q       Date:  2012-06

8.  The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia.

Authors:  Silvana Galderisi; Alessandro Rossi; Paola Rocca; Alessandro Bertolino; Armida Mucci; Paola Bucci; Paola Rucci; Dino Gibertoni; Eugenio Aguglia; Mario Amore; Antonello Bellomo; Massimo Biondi; Roberto Brugnoli; Liliana Dell'Osso; Diana De Ronchi; Gabriella Di Emidio; Massimo Di Giannantonio; Andrea Fagiolini; Carlo Marchesi; Palmiero Monteleone; Lucio Oldani; Federica Pinna; Rita Roncone; Emilio Sacchetti; Paolo Santonastaso; Alberto Siracusano; Antonio Vita; Patrizia Zeppegno; Mario Maj
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

9.  Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia.

Authors:  Jing-Ying Huang; Chih-Min Liu; Tzung-Jeng Hwang; Yu-Jen Chen; Yung-Chin Hsu; Hai-Gwo Hwu; Yi-Tin Lin; Ming-Hsien Hsieh; Chen-Chung Liu; Yi-Ling Chien; Wen-Yih Isaac Tseng
Journal:  Hum Brain Mapp       Date:  2018-01-28       Impact factor: 5.038

10.  The SWITCH study: rationale and design of the trial.

Authors:  Stephan Heres; Diana Meliu Cirjaliu; Liana Dehelean; Valentin Petre Matei; Delia Marina Podea; Dorina Sima; Lynne Stecher; Stefan Leucht
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-07-31       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.